Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Idec and Alnylam to Collaborate on RNAi Therapeutics for PML

NEW YORK (GenomeWeb News) - Biogen Idec and Alnylam will jointly develop RNAi therapeutics to treat progressive multifocal leukoencephalopathy, the companies said today.
 
Biogen Idec will finance all research and development activities and Alnylam will receive an upfront payment of $5 million.
 
Alnylam will also receive more than $51 million in milestone payments, royalties, and utilization fees if the collaboration successfully develops any therapeutic products.
 
Alnylam and Biogen Idec will initially investigate the potential of using RNAi technology to treat infections caused by the JC virus, which results in PML.